Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET


β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological hallmarks of Alzheimer’s disease (AD) and are thought to play crucial roles in a neurodegenerative cascade leading to dementia. Both lesions can now be visualized in vivo using positron emission tomography (PET) radiotracers, opening new opportunities to study disease mechanisms and improve patients’ diagnostic and prognostic evaluation. In a group of 32 patients at early symptomatic AD stages, we tested whether β-amyloid and tau-PET could predict subsequent brain atrophy measured using longitudinal magnetic resonance imaging acquired at the time of PET and 15 months later. Quantitative analyses showed that the global intensity of tau-PET, but not β-amyloid–PET, signal predicted the rate of subsequent atrophy, independent of baseline cortical thickness. Additional investigations demonstrated that the specific distribution of tau-PET signal was a strong indicator of the topography of future atrophy at the single patient level and that the relationship between baseline tau-PET and subsequent atrophy was particularly strong in younger patients. These data support disease models in which tau pathology is a major driver of local neurodegeneration and highlight the relevance of tau-PET as a precision medicine tool to help predict individual patient’s progression and design future clinical trials.

INTRODUCTION
Alzheimer’s disease (AD) is characterized by the co-occurrence of β-amyloid (Aβ) deposition into extracellular plaques and neurofibrillary tangles composed of aggregated hyperphosphorylated tau (1). The aggregation of Aβ and tau is thought to play a crucial role in a neurodegenerative cascade that results in the loss of neurons and synapses (2). The development of radiotracers binding to Aβ plaques (3) and paired helical filaments of tau that comprise neurofibrillary tangles (4) allows the visualization and quantification of AD pathology in living patients using positron emission tomography (PET). Those imaging biomarkers offer an opportunity to improve patient diagnosis and to study the development of AD pathophysiology by describing the relationships between protein aggregation, neurodegeneration, and cognitive impairment.

Cross-sectional neuroimaging studies have demonstrated that lower brain volumes are more strongly associated with tau-PET and therefore precede, regional neurodegeneration in early symptomatic AD (5, 6), suggesting that tau-PET elevation might precede and potentially predict neurodegeneration. Converging evidence also suggests that the intensity and topography of tau-PET, but not Aβ-PET, are strongly associated with the severity of each patient’s specific clinical deficits (10). In addition, earlier age of onset seems to be associated with higher tau-PET signal (8, 11), potentially accounting for the higher rates of brain atrophy observed in patients with early-onset AD compared to their older counterparts (12–14).

Because tau-PET imaging is a relatively novel technique, most previous studies have been based on cross-sectional data, which lead to technical and conceptual limitations. First, cross-sectional studies define neurodegeneration as low volume/metabolism because they cannot directly measure decline in volume/metabolism over time. Resulting metrics are then biased by preexisting interindividual variability in cerebral anatomy and function (15). Second, cross-sectional designs do not allow direct observation of a chronological sequence of biomarker abnormalities. More recently, retrospective longitudinal studies [in which longitudinal magnetic resonance imaging (MRI) data were acquired before tau-PET acquisition] have also highlighted a close association between tau-PET and neurodegeneration (16, 17) but might be biased by the nonlinear nature of atrophy over the disease course (18, 19).

In the present observational study, we prospectively assessed and compared the associations between baseline Aβ and tau-PET burden [using [11C]Pittsburgh compound B (PIB) and [18F]Flortaucipir (FTP), respectively] and subsequent longitudinal atrophy in a group of patients at the early clinical stages of AD. Our primary hypothesis was that the tau deposition detected with FTP-PET drives, and therefore precedes, regional neurodegeneration in early symptomatic AD. From a precision medicine perspective, we were interested...
in testing PET imaging’s ability to predict neuroimaging changes at the individual patient level. On the basis of the cross-sectional evidence described above, we hypothesized that higher baseline FTP-PET, but not PIB-PET, would be associated with higher atrophy rates and that the topography of FTP-PET binding would predict the pattern of subsequent atrophy at the individual patient level. We had two secondary aims. First, we tested whether baseline PIB and FTP-PET data could help predict patients’ clinical deterioration, measured with the clinical dementia rating scale sum of boxes (CDR-SB), a measure of disease severity based on functional decline (20). Last, we investigated whether the previously highlighted association between earlier age of onset and greater atrophy rates could be explained by baseline differences in tau burden.

RESULTS

Description of the cohort

The current study included 32 patients in early clinical stages of AD (mild cognitive impairment or mild dementia, and a positive PIB-PET scan). All patients underwent structural MRI and PET with both PIB and FTP at the baseline visit, and a second structural MRI at a follow-up visit (median time interval, 15 months). Two Siemens 3-T MRI scanners were used in this study (see Materials and Methods and Discussion). Demographics are presented in Table 1. The sample was heterogeneous and included six patients fulfilling criteria for logopenic variant primary progressive aphasia (21) and three patients meeting criteria for posterior cortical atrophy (22). Patients were between 49 and 83 years old at the time of PET scan [20 patients (63%) being under 65 years old].

At the group level, longitudinal atrophy is greater in regions with high baseline FTP binding

For each patient, baseline PET scans were processed to calculate standardized uptake value ratio (SUVR) maps [see (23) and Materials and Methods Table 1. Patients included in the analyses. For continuous variables, mean ± SD [min, max] is indicated. MMSE, mini-mental state examination; CDR-SB, clinical dementia rating scale sum of boxes.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>Female/Male</td>
</tr>
<tr>
<td>Age at baseline</td>
<td>64 ± 9 [49, 83]</td>
</tr>
<tr>
<td>Education</td>
<td>17 ± 3 [12, 24]</td>
</tr>
<tr>
<td>APOE4 alleles: n0/n1/n2 (nmissing)</td>
<td>14/13/3 (2)</td>
</tr>
<tr>
<td>MMSE at baseline</td>
<td>24 ± 4 [14, 30]</td>
</tr>
<tr>
<td>CDR-SB at baseline</td>
<td>3.8 ± 2 [0, 8]</td>
</tr>
<tr>
<td>Baseline to follow-up MRI (months)</td>
<td>15 ± 3 [10, 24]</td>
</tr>
<tr>
<td>Baseline MRI to FTP-PET (months)</td>
<td>1.8 ± 2.2 [0, 7.7]</td>
</tr>
<tr>
<td>Baseline MRI to PIB-PET (months)</td>
<td>1.6 ± 2.3 [0, 7.7]</td>
</tr>
</tbody>
</table>

Table 1. Patients included in the analyses. For continuous variables, mean ± SD [min, max] is indicated. MMSE, mini-mental state examination; CDR-SB, clinical dementia rating scale sum of boxes.
P = 0.12). Pairwise comparisons of correlations in Results and table S1.

Ninety-five percent confidence intervals (95% CI) were computed using bootstrapping with 5000 permutations. Details about the statistical analyses, including a multiple regression with all three baseline predictors, are available in Results and table S1.

The pattern of longitudinal atrophy is shown in Fig. 1B as the group-average reversed Jacobian map (higher values indicating higher atrophy rates) and as a statistical map based on a one-sample t test performed on the 32 Jacobian maps. Atrophy was maximal in the temporoparietal junction and the posterior cingulate/precuneus and moderate in dorsal frontal, occipital, and infero-medial temporal cortices (Fig. 1A).

The pattern of longitudinal atrophy is shown in Fig. 1B as the group-average reversed Jacobian map (higher values indicating higher atrophy rates) and as a statistical map based on a one-sample t test performed on the 32 Jacobian maps. Atrophy was maximal in the temporoparietal junction and the posterior cingulate/precuneus and moderate in dorsal frontal, occipital, and infero-medial temporal cortices (Fig. 1A).

The pattern of longitudinal atrophy is shown in Fig. 1B as the group-average reversed Jacobian map (higher values indicating higher atrophy rates) and as a statistical map based on a one-sample t test performed on the 32 Jacobian maps. Atrophy was maximal in the temporoparietal junction and the posterior cingulate/precuneus and moderate in dorsal frontal, occipital, and infero-medial temporal cortices (Fig. 1A).

The pattern of longitudinal atrophy is shown in Fig. 1B as the group-average reversed Jacobian map (higher values indicating higher atrophy rates) and as a statistical map based on a one-sample t test performed on the 32 Jacobian maps. Atrophy was maximal in the temporoparietal junction and the posterior cingulate/precuneus and moderate in dorsal frontal, occipital, and infero-medial temporal cortices (Fig. 1A).

**Patients with high baseline FTP-PET binding develop more severe cortical atrophy**

We investigated the relationships between baseline cortical alterations (PIB SUVR, FTP SUVR, and cortical thickness) and the severity of subsequent atrophy across patients. Figure 2 shows the associations between baseline global (mean of entire cortex) measures of PIB-SUVR, FTP-SUVR, and cortical thickness [values were derived from FreeSurfer 5.3, Z-scored based on normative dataset (25), and reversed so higher values indicate lower baseline thickness] and overall cortical atrophy (average reversed cortical Jacobian values). Longitudinal cortical atrophy was strongly associated with baseline FTP \( r_{\text{FTP-atrophy}} = 0.670, 95\% \text{ CI } [0.388, 0.841], P < 0.001\), in contrast with weaker correlations with baseline cortical PIB \( r_{\text{PIB-atrophy}} = 0.291, 95\% \text{ CI } [-0.029, 0.546], P = 0.07\) and baseline global cortical thickness \( r_{\text{thickness-atrophy}} = 0.281, 95\% \text{ CI } [-0.067, 0.586], P = 0.12\). Pairwise comparisons of correlations (based on bootstrapping of correlation coefficient pairs with 5000 permutations) showed that longitudinal atrophy was more strongly correlated with FTP than PIB \( (\Delta r = 0.379, 95\% \text{ CI } [0.121, 0.594], P = 0.004)\), but the difference between \( r_{\text{FTP-atrophy}} \) and \( r_{\text{thickness-atrophy}} \) was not significant at \( \alpha = 0.05 \) \( (\Delta r = 0.390, 95\% \text{ CI } [-0.119, 0.821], P = 0.11)\).

When including all three baseline predictors in a single multiple regression model to predict subsequent longitudinal atrophy, FTP remained significant (standardized \( \beta = 0.696, t = 4.2, P < 0.001 \) versus \( \beta = -0.083, t = -0.5, P = 0.58 \) for PIB and \( \beta = 0.173, t = 1.3, P = 0.22 \) for thickness; see table S1), and this full model did not perform better than a model including FTP only to predict longitudinal atrophy (table S1).

**Voxelwise FTP-PET patterns predict maps of subsequent atrophy at the individual patient level**

We next assessed whether the topography of PIB and FTP binding could help predict the pattern of atrophy at the individual patient level, using a voxelwise approach. For each patient, the topographical similarity between 3D maps of PIB PET binding and atrophy was quantified using a voxelwise spatial correlation approach restricted to a cortical mask, as previously described (26) and illustrated in Fig. 3A (see fig. S1 for details on the preprocessing). Resulting spatial correlation coefficients (baseline PIB to longitudinal atrophy and baseline FTP to longitudinal atrophy) were then z-transformed to allow analysis at the group level (see Fig. 3B). Across the 32 patients, spatial correlation between baseline PIB and subsequent atrophy was minimal: mean \( z(r) = 0.183, 95\% \text{ CI } [0.131, 0.226] \) (percentile bootstrap CI based on 5000 permutations), indicating 3% [2%, 5%] shared variance on average. In contrast, the spatial correlation between baseline FTP and longitudinal atrophy was high: mean \( z(r) = 0.780, 95\% \text{ CI } [0.682, 0.859] \), indicating 43% [35%, 48%] shared variance on average. Spatial correlation with longitudinal atrophy was significantly higher for baseline FTP than PIB \( \text{paired t test conducted on the } z(r) \text{ values: } t(31) = 14.9, P < 0.001\) [paired t test conducted on the \( z(r) \) values: \( t(31) = 14.9, P < 0.001\)]. Note that correlations were higher for FTP than for PIB in all 32 patients, as shown in Fig. 3B.

**Baseline tau-PET predicts longitudinal atrophy independent of baseline thickness**

Our finding that baseline FTP-SUVR correlates with subsequent atrophy could be confounded by the fact that these regions are usually
already atrophic at baseline and that atrophy tends to accelerate locally. In addition, low cortical thickness at baseline could reduce the PET signal due to partial volume effects and introduce additional noise in the measurements. We therefore conducted additional analyses to assess the potential confounding effect of "baseline atrophy" on the association between FTP-PET and subsequent atrophy at a regional level. This set of analyses was conducted using regions of interests, enabling the use of partial volume corrected (PVC) PET data. Each patient’s cortex was segmented into 68 regions of interest (ROIs) using FreeSurfer 5.3, and the average cortical thickness was extracted from the baseline MRI for each ROI. Neurodegeneration. Average baseline FTP-SUVRPVC and Jacobian values were also extracted from each ROI (see fig. S2 for details on the preprocessing and Fig. 4A to visualize group averages).

The spaghetti plots in Fig. 4B show that, for most patients, regions with higher baseline FTP-SUVRPVC and, to a smaller extent, lower baseline cortical thickness had higher atrophy rates. Linear mixed-effect models (LMMs) were used to test the respective contribution of each baseline measure to longitudinal atrophy. All ROIs from all patients were included in LMMs (68 × 32 = 2176 entries), with random slopes and intercepts for both ROI and patient factors (see table S2 for further details on model specifications and results). Separate LMMs were first conducted for each predictor, and both were significant (P < 0.001; see Fig. 4B, bottom right panel), although FTPPVC was a stronger predictor (t = 12.6, marginal $R^2 = 0.444$, conditional $R^2 = 0.785$) than baseline thickness (t = 5.1, marginal $R^2 = 0.057$, conditional $R^2 = 0.610$). However, when entering both predictors in the same model (Fig. 4B, bottom line), only FTPPVC was significant (t = 11.9, P < 0.001 versus t = −1.7, P = 0.09 for thickness). In addition, this full model roughly explained the same amount of variance (marginal $R^2 = 0.426$, conditional $R^2 = 0.800$) as the model including baseline FTPPVC only and had a slightly decreased Akaike information criterion (AIC) value (−15,579 versus −15,498; see table S2), indicating that adding baseline thickness only minimally improved the overall model fit. The conclusions of the LMMs were very similar when using non-PVC PET data and when including baseline PIB-SUVR in the model (see fig. S3).

**Baseline tau-PET is more strongly associated with follow-up than baseline cortical thickness**

We hypothesized that baseline tau PET will correlate more strongly with cortical thickness measured at follow-up than at baseline, consistent with a conceptual model in which tau deposition precedes neurodegeneration. Figure 5A shows that, at the group level, baseline tau burden (global cortical FTP-SUVRPVC) correlated more strongly with global cortical thinning (reversed Z-scored thickness) measured at follow-up than baseline ($r = 0.431$, 95% CI [0.166,
Annualized CDR-SB increase was poorly correlated with global cortical measures of baseline PIB SUVR ($r = -0.125$, $P = 0.51$), FTP SUVR ($r = -0.041$, $P = 0.80$), cortical thickness ($r = 0.006$, $P = 0.95$), or longitudinal atrophy ($r = 0.095$, $P = 0.65$; see fig. S4 for 95% CI and scatter plots). Voxelwise analyses showed that increase in CDR-SB over time was associated with longitudinal atrophy in the precuneus/posterior cingulate area (surviving FWE correction at the voxel level; see fig. S4). In contrast, no regional association was found in any of the three baseline predictors (based on the $P_{uncorrected} < 0.001$ threshold).

**Earlier disease onset is associated with higher tau burden and thus more rapid atrophy**

Older age at baseline was associated with lower baseline abnormalities (fig. S5), although the correlation only reached statistical significance (at $\alpha = 0.05$) for baseline FTP-SUVR ($r = -0.572$, $P = 0.002$), but not baseline PIB-SUVR ($r = -0.313$, $P = 0.07$) and baseline thickness ($r = -0.224$, $P = 0.12$; see Fig. 6A for 95% CI and scatter plots). In addition, older patients had lower rates of atrophy (correlation between age and reversed average cortical Jacobian: $r = -0.542$, $P = 0.006$; Fig. 6A). When including both patient’s age
DISCUSSION

In this prospective longitudinal neuroimaging study conducted in patients at early clinical stages of AD, we investigated the associations between baseline PET measures of tau and Aβ burden and subsequent neurodegeneration measured as MRI atrophy over time. In line with our original hypotheses, we found that baseline tau PET, but not Aβ-PET, predicted the degree and spatial distribution of cortical atrophy over the subsequent year.

The association between baseline FTP-PET and subsequent atrophy, and notably the topographical similarity between the two patterns, was a strong and robust finding. The association was found at both the individual patient level (Figs. 1 and 2) and the individual patient levels (Figs. 3 and 4) and using complementary voxelwise (Fig. 3) and ROI-based (Fig. 4 and 5 and fig. S3) approaches. The predictive value of the baseline tau-PET pattern on future atrophy remained substantial even after adjusting for baseline cortical thickness, with tau-PET explaining ~40% of unique variance in longitudinal atrophy. Last, although cross-sectional relationships can be found between tau-PET and concurrent neurodegeneration, we showed that tau-PET more closely resembles neurodegeneration at a future time point (Fig. 5). Together, these longitudinal results expand on previous findings from postmortem and cross-sectional studies, by providing prospective evidence that the aggregation of tau predicts future neurodegeneration in patients with biomarker-confirmed AD. These results support a sequential relationship between tau fibrillar aggregates and downstream degeneration. This directionality is in line with a recent longitudinal tau-PET study from our group showing that, at the clinical stage of AD, tau pathology and brain atrophy progress in different regions, likely reflecting a phase shifting, with tau elevation locally preceding atrophy (27).

Multiple studies (28–31) previously reported that baseline cerebrospinal fluid (CSF) concentration of tau was associated with
higher atrophy rates in heterogeneous groups of patients, although contradicting results exist (32, 33). Our finding of an association between global cortical FTP and global cortical atrophy (Fig. 2A) confirms that this relationship is not driven by the inclusion of AD (high biomarker, high atrophy) and controls or non-AD (low biomarker, low atrophy) patients, but exists within a group of patients with biomarker-confirmed AD. The replicability of the tau biomarker/subsequent atrophy association across biomarker types (fluid versus imaging) is also consistent with the relationships found between PET and CSF measures of tau (23, 34, 35). The topographical information embedded in the PET data constitutes a major advantage compared to CSF markers. We demonstrated that tau-PET is not only predictive of how much but also of where atrophy will occur, which has major implications for patient prognosis and clinical trials.

Our findings suggest that tau-PET could be useful for the design of clinical trials and could increase the ability to detect a treatment effect even over a relatively short time frame (36, 37). First, tau-PET could be used to enrich trials with patients with tau-PET signal predictive of upcoming atrophy or to stratify patients in trials based on the degree of expected atrophy in the upcoming year. Second, tau-PET could help determine how (i.e., where) atrophy should be measured to maximize study sensitivity. A major issue of using MRI to monitor disease progression is the interindividual heterogeneity in atrophy patterns (38), even when selecting patients with a classic amnestic phenotype as in the Alzheimer’s Disease Neuroimaging Initiative (12, 39). A given generic ROI (e.g., the hippocampus) would not optimally capture every patient’s brain atrophy [e.g., patients with “hippocampal-sparing AD” (38, 40)]. Alternative options exist to maximize detection of AD atrophy using data-driven ROIs (41) or adapting the ROI to specific phenotypes (42), but our data suggest that PET could be used to create patient-tailored, FTP-informed ROIs for atrophy detection. This approach could capture tau-mediated neurodegeneration in every patient in a more optimal manner, agnostic of any a priori assumptions. Alternatively, the tight relationship between tau and atrophy might imply that, in regions with elevated tau-PET signal, the pathological cascade leading to neurodegeneration has already been triggered and that neurodegeneration processes are now uncoupled from tau pathology. In that case, anti-tau therapies could be more effective in preventing atrophy in regions with low to mild tau-PET signal, whereas atrophy in high tau-PET regions would be difficult to modify with anti-tau therapies.

Clinical decline measured with the CDR-SB was associated with atrophy in the precuneus but was not correlated with baseline FTP-PET. This weak relationship might be related to methodological factors: the small sample size, the intrinsic noise of measuring clinical progression based on two time points, or the use of memory-centric

---

**Fig. 6. Effect of patient age on baseline tau pathology and subsequent atrophy.** (A) Association between patient age and global cortical FTP-SUVR at baseline and longitudinal atrophy; see fig. S5 for associations between age and other variables. Mediation analysis showed that baseline cortical FTP-SUVR mediated the effect of age on longitudinal atrophy; see fig. S6 for the nonsignificant mediation models conducted with baseline PIB and baseline thickness instead of baseline FTP. (B) Voxelwise analyses showing the regional associations between increasing patient’s age and lower FTP-SUVR or atrophy rates (see fig. S7 for unthresholded maps and https://neurovault.org/collections/WLOOMCMY/ to access the 3D maps). (C) Association between patient’s age and the topographical similarity between patterns of baseline FTP-SUVR and subsequent atrophy measured using voxelwise spatial correlation (as described in Fig. 3); see fig. S5 for similar plot with PIB.
CDR-SB in a clinically diverse cohort like ours that includes language, and visuospatial-predominant AD phenotypes. Alternatively, the lack of correlation with FTP could also reflect the indirect relationship between tau pathology and clinical deficits that is thought to be at least partly mediated by brain degeneration (10).

In contrast to tau-PET, neither the burden nor topography of Aβ-PET was a strong predictor of future atrophy. This is consistent with multiple reports that Aβ-PET has no or weak relationships with the patterns of neurodegeneration or clinical deficits that is thought to be at least partly mediated by brain degeneration (10).

The relationship between tau pathology and clinical deficits that is thought to be at least partly mediated by brain degeneration is also consistent with autopsy data (45, 46). To our knowledge, the relationships between baseline volume or thickness and future atrophy have not been thoroughly investigated, but studies have suggested that atrophy accelerates over time, before decelerating in later stages (18, 19). This nonlinear relationship might explain why we could not identify consistent and robust relationships between baseline MRI findings and subsequent atrophy.

Baseline tau-PET accounted for ~40 to 50% of the severity and topography of subsequent atrophy in our cohort. Future investigations will be needed to study additional predictors of atrophy [e.g., inflammation (47), nonlocal effects of pathology (48, 49), or additional brain pathologies (50)] to further our understanding of the complex mechanisms underlying neurodegeneration in AD.

Our analyses identified patient’s age as an important factor regarding not only the severity of tau burden and brain atrophy but also the relationship between pathology and longitudinal atrophy. First, we replicated previous findings that later age of disease onset is associated with lower tau-PET burden (8, 11) and longitudinal atrophy rates (12–14). Moreover, we showed that the temporal association between FTP and longitudinal atrophy sharply decreased with patient’s age (Fig. 5), in line with a recent cross-sectional study (51).

Together, these results are consistent with the idea that early-onset AD might constitute a more pure form of AD in which neurodegeneration is mainly driven by AD pathology, whereas later-onset clinical AD is multifactorial, associated with distinctive risk factors, and related to more frequent comorbidities and co-pathologies (52, 53). Previous clinicopathological studies showed that the relationship between AD neuropathology and dementia decreased in older patients (54). Together, growing evidence suggests that potential disease-modifying drugs that specifically target AD neuropathology may benefit patients with earlier-onset AD more than older patients.

A number of study features and limitations should be highlighted to appropriately interpret our results. First, note that PET signal is only a proxy for underlying pathology, and although postmortem studies suggest that FTP binds to paired helical filaments of tau (55, 56), “off target” signal unrelated to tau in the basal ganglia (57, 58) and in some tau-negative conditions (59, 60) raises questions about specificity. Second, the sample size was modest, though similar to previous cross-sectional tau-PET/atrophy association studies. The use of complementary robust statistical approaches, and the inspection of all scatter plots and images, showed that results were not influenced by outliers. Third, the patients included in our study constitute an academic-based cohort of diverse and relatively young patients, which may limit generalizability. Note that the results remained unchanged when excluding non-amnestic variants (language or visuospatial phenotypes of AD; see fig. S8).

Fourth, our cohort encompassed early clinical stages of AD, and the results cannot be extrapolated to earlier (i.e., preclinical) or more severe stages of the disease, when neurodegeneration might be associated or driven by distinct mechanisms. Fifth, because of the recent development of FTP, patients only had one follow-up MRI after the baseline visit, and additional time points would enable a more precise characterization of atrophy trajectories. Future studies will be needed to determine the prognostic value of baseline tau-PET over longer follow-up. Similarly, clinical decline was evaluated on the basis of two time points only, and more data would be needed to improve signal to noise; the limited available time points, together with the heterogeneity of the cohort, might account for the lack of associations between baseline tau-PET and clinical decline. Last, our patients underwent MRI scanning on two different Siemens 3-T scanners, which might have added noise to the estimation of longitudinal atrophy. However, further analyses showed that the present results were found independently of MRI scanning protocol (fig. S9).

In summary, our study illustrates the potential of PET imaging to identify the pathological drivers of neurodegeneration in AD and to help predict individual patients’ future evolution. These results outline the robust local relationships between accumulation of tau-containing paired helical filament and neurodegeneration, emphasizing tau as a relevant target for disease-modifying drugs at this early clinical stage (61). Additional studies will be needed to extend our approach to larger cohorts, notably considering additional disease stages, older age of onset, and longer follow-up duration.

**MATERIALS AND METHODS**

**Experimental design**

The main objective of this study was to test whether amyloid and tau-PET could predict future brain atrophy in patients at symptomatic stages of AD. Data were derived from an ongoing longitudinal observational study including repeated PIB, PIB-PET, and FTP-PET in patients with a clinical diagnosis of AD at the mild cognitive impairment or dementia stage. No power analysis was performed before the study, but the sample size is within the range of previous papers assessing relationships between tau-PET and brain volume in symptomatic patients (6–7, 17). Data preprocessing steps were performed using automated pipeline agnostic of the baseline tau- and amyloid-PET data. Quality control of the preprocessing steps was done blind to the baseline PET measures. No outlier was detected, and all data were included in all analyses and plotted on each figure.

**Patients**

All patients underwent a comprehensive clinical evaluation (10) at the University of California, San Francisco (UCSF) Memory and Aging Center. We selected patients who (i) had a clinical diagnosis of AD [at either the mild cognitive impairment or dementia stage (62, 63)], (ii) had undergone 3-T structural MRI, FTP-PET, and PIB-PET at their baseline visit, (iii) had a positive PIB-PET [based on visual read (64)], and (iv) had a follow-up 3-T MRI at least 9 months after the first visit. By 1 December 2018, 36 patients fulfilled these criteria, but 4 were excluded because of movement artifacts on an MRI and/or failure of the longitudinal MRI pipeline. The remaining 32 patients were included in the analyses.
Written informed consent was obtained from all patients or their surrogates. The study was approved by the University of California (San Francisco and Berkeley) and Lawrence Berkeley National Laboratory institutional review boards for human research.

**Image acquisition**

T1-weighted magnetization-prepared rapid gradient echo MRI sequences were acquired at UCSF, on either a 3-T Siemens Tim Trio or a 3-T Siemens Prisma Fit scanner. Both scanners had very similar acquisition parameters (sagittal slice orientation; slice thickness, 1.0 mm; slices per slab, 160; in-plane resolution, 1.0 × 1.0 mm; matrix, 240 × 256; repetition time, 2300 ms; inversion time, 900 ms; flip angle, 9°), although echo time slightly differed (Trio, 2.98 ms; Prisma, 2.9 ms).

PET data were acquired on a Siemens Biograph PET/computed tomography (CT) scanner at the Lawrence Berkeley National Laboratory. Both radiotracers were synthesized and radiolabeled at the Lawrence Berkeley National Laboratory’s Biomedical Isotope Facility. Here, we analyzed PET data that were acquired from 50 to 70 min after the injection of ~15 mCi of PIB (four 5-min frames) and 80 to 100 min after the injection of ~10 mCi of FTP (four 5-min frames). A low-dose CT scan was performed for attenuation correction before PET acquisition, and PET data were reconstructed using an ordered subset expectation maximization algorithm with weighted attenuation and smoothed with a 4-mm Gaussian kernel with scatter correction (calculated image resolution, 6.5 × 6.5 × 7.25 mm based on Hoffman phantom).

**SUVR calculation**

Each patient’s baseline MRI was segmented using FreeSurfer 5.3 (https://surfer.nmr.mgh.harvard.edu/) and Statistical Parametric Mapping 12 (SPM12; Wellcome Department of Imaging Neuroscience, Institute of Neurology, London, UK) to create tracer-specific PET reference regions. PET frames were realigned, averaged, and coregistered onto their corresponding MRI. SUVR images were created using FreeSurfer-defined cerebellar GM for PIB-PET. For FTP, FreeSurfer segmentation was combined with the SUIT template (65) (which was reverse-normalized to each patient individual space using SPM12) to only include inferior cerebellum voxels, therefore avoiding contamination from off-target binding in the dorsal cerebellum (58, 66).

**Longitudinal pipeline and voxelwise analyses**

For each patient, the baseline and follow-up MRIs were processed using SPM12 pairwise longitudinal registration (24), creating a within-patient midpoint average MRI and a 3D Jacobian rate map reflecting an annualized measure of volumetric change. In this original Jacobian map, negative values indicate contraction over time (e.g., classically in the brain), whereas positive values indicate expansion (e.g., in the ventricles). The Jacobian maps were reversed (i.e., multiplied by −1), so higher values in the cortex indicate greater atrophy. PIB and FTP-SUVR images were moved from baseline MRI space to the midpoint average MRI space using SPM12’s deformation toolbox, to be aligned with the Jacobian rate map.

The mid-point average MRI was then segmented into GM, white matter, and CSF. The tissue segments were used to derive a binary GM mask, which was later masked to exclude basal ganglia [because of FTP off-target binding (57) and relative sparing in AD] and cerebellum (i.e., PET reference region) using the Hammers atlas (67), resulting in a binary cerebral cortical mask (see fig. S1 for illustration).

The reversed Jacobian rate map and the PET-SUVR images were finally smoothed within this mask using AFNI 3dBlurInMask command and applying differential kernels (4 mm for PET and 8 mm for Jacobians), so all three images had equivalent final smoothness (fig. S1). These images were used to calculate spatial correlations between patterns of atrophy (Jacobian values) and PET binding (Fig. 3).

PIB, FTP, and Jacobian maps from all patients were warped to Montreal Neurological Institute space using the deformation parameters estimated during the midpoint average MRI segmentation step and averaged to create across patient averages for PIB SUVR, FTP SUVR, and Jacobians (Fig. 1). Template-warped Jacobian maps were entered in a voxelwise one-sample t test to detect areas of significant atrophy (reversed Jacobians > 0) over time (Fig. 1). All voxelwise results were presented using an uncorrected voxel threshold of $P < 0.001$ combined with a corrected cluster threshold of $P_{\text{FWE}} < 0.05$; voxels that reached more conservative voxel-level thresholds ($P_{\text{FWE}} < 0.05$ and $P_{\text{FWE}} < 0.001$) were also highlighted.

**FreeSurfer segmentation and ROI analyses**

To quantify baseline cortical neurodegeneration (i.e., in a cross-sectional design), we used the FreeSurfer segmentation outputs derived from the previous step (see the “SUVR calculation” section) and based on the first MRI. The average thickness measure of each of the 68 cortical ROIs was extracted from each patient’s FreeSurfer directory and converted into a Z score based on the code and the data provided by Potvin et al. (25). Briefly, patients’ thickness values were converted into Z scores denoting the deviation from their expected values, as calculated based on the patient’s characteristics (age, sex, estimated total intracranial volume, scanner manufacturer, and magnetic field strength) and a normative multicentric sample of 2713 healthy controls aged 18 to 94 years. This approach was previously used to quantify cortical thickness in AD (68).

To assess the correlation between the patterns of baseline GM and subsequent atrophy (i.e., are regions that shrink over time already abnormally small at baseline?), we extracted the average SPM12-generated Jacobian values from each of the 68 FreeSurfer ROIs for each patient. Average FTP-PET SUVR values were extracted from all 68 ROIs using a PVC algorithm based on geometric transfer matrix technique [see (58, 66)]. LMEMs were run including all ROIs from all patients (including random slopes and intercepts for both factors), with longitudinal atrophy (Jacobian values) as the dependent variable, and baseline thickness Z score and/or FTP-SUVR PVC as predictors.

**Statistical analyses**

All statistical analyses were conducted using MATLAB 2015a (MathWorks Inc., www.mathworks.com/) and the Robust correlation toolbox (69) to calculate Pearson correlation estimates and percentile bootstrap CI (from which $P$ values were derived). Jamovi (www.jamovi.org) was used to conduct multiple regressions, analyses of variance (ANOVAAs), mediation analyses, and LMEMs using dedicated modules. Details about each specific analysis are provided with the description of the analyses in Results or the Supplementary Materials.

Imaging results were displayed on 3D brain surfaces using BrainNet Viewer (70) and gseg (https://lcbc-uio.github.io/ggseg/). Data file S1 contains most of the data used in the analyses presented in the article.
Fig. S4. Associations between neuroimaging measures and clinical decline.

10. B. Bettcher, K. Mintun; 18F-AV-1451-A05 investigators, Relationships between flortaucipir PET and longitudinal atrophy (related to Fig. 6).

Fig. S5. Associations between neuroimaging measures and global neuroimaging measures (related to Fig. 6).

Fig. S6. Summary of bivariate associations and mediation models between global cortical neuroimaging measures at baseline, global cortical longitudinal atrophy, and age (related to Fig. 6).

Fig. S7. Voxelwise associations between patient's age, baseline FP-T PET, and longitudinal atrophy (related to Fig. 6).

Fig. S8. Analyses of the influence of atypical AD phenotypes on the main results.

Fig. S9. Analyses of the influence of MRI scanner switch on the main results.

Table S1. Details of linear regression models presented in Fig. 2.
Table S2. Details of LMEms shown in Fig. 4.

Data file S1. Data used for the analyses presented in the manuscript.

View/request a protocol for this paper from Bio-protocol.
correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.


5. B. D. James, D. A. Bennett, P. A. Boyle, S. Leurgans, J. A. Schneider, Dementia from Alzheimer disease and mixed pathologies in the elderly population. JAMA Neurol. 70, 1798–1800 (2013).


Competing interests: D.C.P. receives support from the NIH (K23AG045289). J.C.R. receives support from the NIH (R01 AG038791 PI, Adam Boxer) and travel funds from Eli Lilly. S.L.B. consults for Genentech. W.W.S. receives research support from NIH/NIA and has received consulting fees from Merck Inc., Biogen Idec, and Bristol-Myers Squibb. H.J.R. receives research support from the NIH/National Institute on Aging, RO1 AG032306 (PI), PO1 AG019724 (Core leader), AG045333 (PI), and AG023501 (Core leader). R.M.T. receives research support from the University of California. R.M.T. also consulted for ExpertConnect and Grifols. B.L.M. receives research support from the NIH/NIA and the Centers for Medicare & Medicaid Services (CMS) as grants for the Memory and Aging Center. As an additional disclosure, B.L.M. serves as Medical Director for the John Douglas French Foundation; Scientific Director for the Tau Consortium; Director/Medical Advisory Board of the Larry L. Hillblom Foundation; Scientific Advisory Board Member for the National Institute for Health Research Cambridge Biomedical Research Centre and its subunit, the Biomedical Research Unit in Dementia (UK); and Board Member for the American Brain Foundation (ABF). W.J.J. has served as a consultant to BioClinica, Genentech, and Novartis Pharmaceuticals. G.D.R. receives research support from Avid Radiopharmaceuticals, GE Healthcare, and Life Molecular Imaging and has received consulting fees or speaking honoraria from Axon Neurosciences, Roche, Eisai, Genentech, Merck. The other authors declare that they have no competing interests.

Data and materials availability: Most data associated with this study are available in the main text, supplementary data file, or on neurovault for group-level voxelwise images (https://neurovault.org/collections/WLDODMCY/). Individual MRI and PET images data will be shared with external investigators upon submission of a proposal and under a data transfer agreement.

Submitted 3 August 2018
Resubmitted 13 September 2019
Accepted 13 November 2019
Published 1 January 2020
10.1126/scitranslmed.aau5732

Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET


Sci Transl Med 12, eaau5732.
DOI: 10.1126/scitranslmed.aau5732

Predictive PET
Understanding the dynamic of the two major hallmark of Alzheimer's disease (AD), tau protein and β-amyloid, in the brain could allow better disease management. The use of positron emission tomography (PET) with specific radiotracers allows the visualization of tau-containing neurofibrillary tangles and β-amyloid plaques in vivo. Now, La Joie et al. performed longitudinal analysis of tau-PET and β-amyloid–PET in 32 patients with AD starting at early disease stage and correlated the signal with brain atrophy at later stages. In this cohort, tau-PET, but not β-amyloid–PET, signal could predict brain atrophy at later stages. Tau-PET might be useful for predicting disease progression and for designing and evaluating new therapies.

ARTICLE TOOLS
http://stm.sciencemag.org/content/12/524/eaau5732

SUPPLEMENTARY MATERIALS
http://stm.sciencemag.org/content/suppl/2019/12/23/12.524.eaau5732.DC1

RELATED CONTENT
http://stm.sciencemag.org/content/scitransmed/11/490/eaat8462.full
http://stm.sciencemag.org/content/scitransmed/11/474/eaau6550.full
http://stm.sciencemag.org/content/scitransmed/11/507/eaav6221.full
http://stm.sciencemag.org/content/scitransmed/8/338/338ra66.full
http://stm.sciencemag.org/content/scitransmed/12/534/eaau4069.full
http://stm.sciencemag.org/content/scitransmed/12/543/eaau2939.full
http://science.sciencemag.org/content/sci/370/6519/eaay8826.full
http://stm.sciencemag.org/content/scitransmed/13/577/eabc0655.full
http://science.sciencemag.org/content/sci/371/6529/eabb4309.full
http://stm.sciencemag.org/content/scitransmed/13/593/eabb8394.full

REFERENCES
This article cites 70 articles, 7 of which you can access for free
http://stm.sciencemag.org/content/12/524/eaau5732#BIBL

PERMISSIONS
http://www.sciencemag.org/help/reprints-and-permissions

Use of this article is subject to the Terms of Service

Science Translational Medicine (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title Science Translational Medicine is a registered trademark of AAAS.

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works